04 September 2019
Visiongain has launched a new pharma report Acute Repetitive Seizures Market Forecast 2019-2029: By Product (USL-261, NRL-1, AZ-002, Diastat Rectal Gel), By Region and Segment Forecasts.
The global Acute Repetitive Seizures market is poised for rapid growth between 2019 and 2029. High unmet medical clinical for patients, as well as caregivers and the availability of an advanced product pipeline are some of the main factors that should favor market growth. Drug therapy is effective for most patients with cluster convulsions. However, there are a significant number of therapeutic challenges and unmet medical needs including drug-induced seizures, adverse reactions and a lack of anti-epileptic agents that can prevent the development of convulsions and its comorbidities.
The market is currently driven by generic drugs that mainly include oral benzodiazepines (diazepam and lorazepam). Rectal diazepam is the only drug approved for use in the United States and buccal midazolam in the European Union. Other drugs, such as diazepam (oral and intramuscular), midazolam (oral, intranasal, intramuscular), lorazepam (oral, intranasal, sublingual) and progesterone are mainly used off label. The market should be consolidated with a few large companies and high market shares.
Leading companies featured in the report include UCB S.A. Belgium, Neurelis, Valeant Pharmaceuticals North America LLC., Alexza Pharmaceuticals, VERITON PHARMA and others
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global wound care market is big, and only set to grow bigger. Currently, estimates show a CAGR of 4.6% in the years to come, with the overall market growing from US$19.8 billion in 2019 to US$24.8 billion by 2024. The industry is ripe with opportunity, with that growth coming from several factors – but most especially growth in emerging …
30 March 2020
Nasal Sprays segment held the largest market share of the global nasal drug delivery technology market in 2019.
30 March 2020
New technologies will be needed to ensure that scaling-up of manufacturing operations can be done effectively once stem cell treatments enter the market.
24 March 2020
As per the latest reports of UNCTAD (United Nations Conference on Trade and Development), COVID-19 pandemic has not only led to tragic human consequences but is projected to cost the global economy $1 trillion in 2020.